Developer of a DNA testing kit designed to improve dog health and wellness.
Developer of a DNA testing kit designed to improve dog health and wellness.
Other Consumer Durables📍 Boston, MAFounded 2015
Current Valuation
$700M
as of 2021-Q3
PRIVATE
QL Price
$700M
0% vs last round
QuantLogix's current estimate for Embark, published 2026-09-27 — in line with the last disclosed round of $700M (2021-Q3).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$700M
2021-Q3
weight 0.03
How this price has held up
No round has priced for Embark since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Embark, 2026-09-27 (e115252b0c1ba373).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Embark going public?
No. Embark is private and has not filed to go public. There is no S-1 on file.
What is Embark's valuation in 2026?
Embark is valued at $700M as of 2021-Q3, set by its Series B ($75M, Jul 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Embark filed an S-1?
No public S-1 is on file for Embark.
How much has Embark raised?
Embark has raised $94.53M in total, most recently a Series B of $75M in Jul 2021.
Is Embark publicly traded — can you buy Embark stock?
No. Embark is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Embark on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2015
HQ
Boston, MA
Employees
90
Total Raised
$94.53M
Last Round
Series B — $75M (Jul 2021)
IPO Status
private
Fundraising Status
Series B · $75M · 5y 2mo ago
privateTotal raised $94.53M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series B
$75M
Jul 2021
—
$700M
Talent Signal
Hiring trend
▲ Hiring uptrend
+75% vs 2026-08
Open roles
7
via careers page
Product-build share
57%
engineering, research, product, design
Trajectory
scaling
product-led hiring — 57% of open roles build product; the rest are go-to-market and G&A.
Executive bench growing while hiring expands: 2 senior hires (CFO, CRO); open roles trending up.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Key Executive Moves
INNaseem AnzariCFO · 2026-08-24
INLaura NealCRO · 2026-08-24
From trusted-source news extraction (deep-enrich pipeline); dates approximate publication, not effective date.
Our researchScience and research[Our research](https://embarkvet.com/blogs/resources/tagged/our-research)[Science and research](https://embarkvet.com/pages/science-and-research)Skip to content![Embark dog DNA test brand logo, yellow mark with black "embark" wordmark
Counted from Embark's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health CareVeterinaryPet
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q3. Refreshed quarterly.